ReviewInflammation research : official journal of the European Histamine Research Society ... [et al.]2026
B cell-driven immune remodeling in inflammatory bowel disease: links to pathogenesis and therapeutic failure.
Review in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveInflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by dysregulated intestinal immune responses. Accumulating evidence indicates that B-lineage cells play important roles in shaping mucosal immunity. This review aims to summarize the physiological and pathological roles of intestinal B-lineage cells in IBD, with a particular focus on their functional remodeling during biologic therapy and emerging strategies to overcome biologic resistance.
methodsRelevant literature on B-lineage cells, IBD, mucosal immunity, and biologic therapies was searched and reviewed.
resultsUnder physiological conditions, plasmablasts and plasma cells maintain intestinal homeostasis through IgA secretion, whereas B lymphocytes contribute via cytokine production, antigen presentation, and cellular interactions that support epithelial repair and barrier integrity. In IBD, B-lineage cells undergo pathogenic remodeling, with expanded effector subsets exhibiting enhanced inflammatory cytokine production, altered antibody profiles, and increased interactions with T cells, myeloid cells, and stromal cells. These changes disrupt epithelial integrity and sustain maladaptive immune activation, contributing to chronic mucosal inflammation. Biologic therapies targeting TNF, α4β7 integrin, and IL-12/23 exert direct and indirect effects on B-lineage cells, modulating their trafficking, survival, and functional states, and partially restoring immune balance. Nevertheless, persistent cellular plasticity and dysregulated survival signaling may enable pathogenic B-lineage subsets to retain inflammatory potential, contributing to treatment non-response or secondary loss of efficacy.
conclusionB-lineage cells play critical roles in both intestinal homeostasis and IBD pathogenesis. Understanding their functional remodeling during biologic therapy may provide insights into treatment resistance and inform emerging strategies to overcome biologic resistance in IBD.
Indexed as
Identifiers
41961250What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.